Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.35 Million EUR | -17.33% |
| 2022 | 47.59 Million EUR | -46.63% |
| 2021 | 89.18 Million EUR | -14.02% |
| 2020 | 103.73 Million EUR | 40.76% |
| 2019 | 73.69 Million EUR | -3.09% |
| 2018 | 76.04 Million EUR | 556.75% |
| 2017 | 11.57 Million EUR | 15.93% |
| 2016 | 9.98 Million EUR | -17.1% |
| 2015 | 12.04 Million EUR | 19.12% |
| 2014 | 10.11 Million EUR | -90.43% |
| 2013 | 105.72 Million EUR | 31.64% |
| 2012 | 80.31 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 24.46 Million EUR | -18.17% |
| 2024 Q1 | 29.89 Million EUR | -24.04% |
| 2023 Q3 | 44.04 Million EUR | 23.08% |
| 2023 Q4 | 39.35 Million EUR | -10.66% |
| 2023 FY | 39.35 Million EUR | -17.33% |
| 2023 Q1 | 42.86 Million EUR | -9.94% |
| 2023 Q2 | 35.78 Million EUR | -16.52% |
| 2022 FY | 47.59 Million EUR | -46.63% |
| 2022 Q1 | 75.83 Million EUR | -14.97% |
| 2022 Q3 | 55.29 Million EUR | -18.78% |
| 2022 Q4 | 47.59 Million EUR | -13.92% |
| 2022 Q2 | 68.08 Million EUR | -10.21% |
| 2021 Q1 | 101.74 Million EUR | -1.91% |
| 2021 FY | 89.18 Million EUR | -14.02% |
| 2021 Q4 | 89.18 Million EUR | 3.13% |
| 2021 Q3 | 86.47 Million EUR | -10.98% |
| 2021 Q2 | 97.14 Million EUR | -4.52% |
| 2020 Q2 | 60.64 Million EUR | -7.87% |
| 2020 FY | 103.73 Million EUR | 40.76% |
| 2020 Q1 | 65.83 Million EUR | -10.67% |
| 2020 Q4 | 103.73 Million EUR | 70.27% |
| 2020 Q3 | 60.92 Million EUR | 0.46% |
| 2019 Q3 | 63.31 Million EUR | -4.46% |
| 2019 Q2 | 66.27 Million EUR | -2.09% |
| 2019 Q1 | 67.68 Million EUR | -10.99% |
| 2019 FY | 73.69 Million EUR | -3.09% |
| 2019 Q4 | 73.69 Million EUR | 16.39% |
| 2018 Q3 | 13.22 Million EUR | 7.19% |
| 2018 Q2 | 12.33 Million EUR | 0.06% |
| 2018 Q1 | 12.32 Million EUR | 6.46% |
| 2018 FY | 76.04 Million EUR | 556.75% |
| 2018 Q4 | 76.04 Million EUR | 475.18% |
| 2017 Q3 | 11.54 Million EUR | -11.74% |
| 2017 Q4 | 11.57 Million EUR | 0.26% |
| 2017 FY | 11.57 Million EUR | 15.93% |
| 2017 Q2 | 13.08 Million EUR | 38.44% |
| 2017 Q1 | 9.45 Million EUR | -5.37% |
| 2016 FY | 9.98 Million EUR | -17.1% |
| 2016 Q3 | 10.03 Million EUR | 10.5% |
| 2016 Q2 | 9.08 Million EUR | -16.23% |
| 2016 Q1 | 10.84 Million EUR | -10.02% |
| 2016 Q4 | 9.98 Million EUR | -0.48% |
| 2015 FY | 12.04 Million EUR | 19.12% |
| 2015 Q3 | 9.4 Million EUR | -0.67% |
| 2015 Q2 | 9.47 Million EUR | 9.67% |
| 2015 Q1 | 8.63 Million EUR | -14.6% |
| 2015 Q4 | 12.04 Million EUR | 28.05% |
| 2014 Q1 | 121.91 Million EUR | 15.32% |
| 2014 Q3 | 10.07 Million EUR | -90.49% |
| 2014 Q4 | 10.11 Million EUR | 0.36% |
| 2014 Q2 | 106.02 Million EUR | -13.03% |
| 2014 FY | 10.11 Million EUR | -90.43% |
| 2013 Q4 | 105.72 Million EUR | 0.0% |
| 2013 FY | 105.72 Million EUR | 31.64% |
| 2012 FY | 80.31 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 73.776% |
| Dynavax Technologies Corporation | 375.02 Million USD | 89.507% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 42.771% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.943% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 91.928% |
| Perrigo Company plc | 6.04 Billion USD | 99.349% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 85.136% |
| Illumina, Inc. | 4.36 Billion USD | 99.099% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.924% |
| Nektar Therapeutics | 267.04 Million USD | 85.265% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 79.897% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.809% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 84.658% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -5.519% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.918% |
| Waters Corporation | 3.47 Billion USD | 98.868% |
| Biogen Inc. | 12.04 Billion USD | 99.673% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 52.264% |
| Adicet Bio, Inc. | 37.12 Million USD | -6.008% |
| Evolus, Inc. | 209.68 Million USD | 81.234% |
| bluebird bio, Inc. | 424.62 Million USD | 90.733% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 2.178% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 94.045% |
| FibroGen, Inc. | 585.72 Million USD | 93.282% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.2% |
| Homology Medicines, Inc. | 118.53 Million USD | 66.802% |
| Geron Corporation | 146.12 Million USD | 73.071% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.029% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -11.862% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 93.63% |
| Myriad Genetics, Inc. | 312.9 Million USD | 87.424% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.446% |
| OPKO Health, Inc. | 622.47 Million USD | 93.679% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -96.054% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 84.311% |
| Zoetis Inc. | 9.29 Billion USD | 99.577% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 19.981% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.877% |
| Exelixis, Inc. | 678.44 Million USD | 94.2% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.236% |
| uniQure N.V. | 624.01 Million USD | 93.694% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 18.774% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -213.946% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 90.095% |
| Verastem, Inc. | 71.18 Million USD | 44.722% |
| Imunon, Inc. | 8.53 Million USD | -361.29% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.489% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.364% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.14% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 65.727% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.614% |
| TG Therapeutics, Inc. | 169.08 Million USD | 76.728% |
| Blueprint Medicines Corporation | 918.64 Million USD | 95.716% |
| Insmed Incorporated | 1.66 Billion USD | 97.632% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 68.794% |
| Incyte Corporation | 1.59 Billion USD | 97.529% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 96.681% |